XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Statements of Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2021     92,960,066        
Beginning balance at Dec. 31, 2021 $ 73,128 $ (98,632) $ 1 $ 841,255 $ (112,052) $ (768,128) $ 13,420
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock upon exercise of options (in shares)     417,428        
Issuance of common stock upon exercise of options 637     637      
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for employee taxes (in shares)     922,610        
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for employee taxes (2)     (2)      
Stock-based compensation expense 12,964     12,964      
Net loss (57,412)         (57,412)  
Ending balance (in shares) at Mar. 31, 2022     94,300,104        
Ending balance at Mar. 31, 2022 (69,317)   $ 1 742,802   (812,120)  
Beginning balance (in shares) at Dec. 31, 2022     99,088,172        
Beginning balance at Dec. 31, 2022 (170,092)   $ 1 781,060   (951,153)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for employee taxes (in shares)     1,064,260        
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for employee taxes (208)     (208)      
Stock-based compensation expense 9,280     9,280      
Net loss (82,500)         (82,500)  
Ending balance (in shares) at Mar. 31, 2023     100,152,432        
Ending balance at Mar. 31, 2023 $ (243,520)   $ 1 $ 790,132   $ (1,033,653)